Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study

for the Diabetes Prevention Program Research Group

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

The largest and longest clinical trial of metformin for the prevention of diabetes is the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study (DPP/DPPOS). In this review, we summarise data from the DPP/DPPOS, focusing on metformin for diabetes prevention, as well as its long-term glycaemic and cardiometabolic effects and safety in people at high-risk of developing diabetes. The DPP (1996–2001) was a RCT of 3234 adults who, at baseline, were at high-risk of developing diabetes. Participants were assigned to masked placebo (n = 1082) or metformin (n = 1073) 850 mg twice daily, or intensive lifestyle intervention (n = 1079). The masked metformin/placebo intervention phase ended approximately 1 year ahead of schedule because of demonstrated efficacy. Primary outcome was reported at 2.8 years. At the end of the DPP, all participants were offered lifestyle education and 88% (n = 2776) of the surviving DPP cohort continued follow-up in the DPPOS. Participants originally assigned to metformin continued to receive metformin, unmasked. The DPP/DPPOS cohort has now been followed for over 15 years with prospective assessment of glycaemic, cardiometabolic, health economic and safety outcomes. After an average follow-up of 2.8 years, metformin reduced the incidence of diabetes by 31% compared with placebo, with a greater effect in those who were more obese, had a higher fasting glucose or a history of gestational diabetes. The DPPOS addressed the longer-term effects of metformin, showing a risk reduction of 18% over 10 and 15 years post-randomisation. Metformin treatment for diabetes prevention was estimated to be cost-saving. At 15 years, lack of progression to diabetes was associated with a 28% lower risk of microvascular complications across treatment arms, a reduction that was no different among treatment groups. Recent findings suggest metformin may reduce atherosclerosis development in men. Originally used for the treatment of type 2 diabetes, metformin, now proven to prevent or delay diabetes, may serve as an important tool in battling the growing diabetes epidemic. Long-term follow-up, currently underway in the DPP/DPPOS, is now evaluating metformin’s potential role, when started early in the spectrum of dysglycaemia, on later-stage comorbidities, including cardiovascular disease and cancer. Trial registration: ClinicalTrials.gov NCT00038727 and NCT00004992.

Original languageEnglish (US)
Pages (from-to)1601-1611
Number of pages11
JournalDiabetologia
Volume60
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Metformin
Outcome Assessment (Health Care)
Placebos
Life Style
Safety
Gestational Diabetes
Risk Reduction Behavior
Therapeutics
Random Allocation
Type 2 Diabetes Mellitus
Comorbidity
Fasting
Atherosclerosis
Appointments and Schedules
Cardiovascular Diseases
Economics
Clinical Trials

Keywords

  • Diabetes prevention
  • DPP
  • DPPOS
  • Impaired glucose tolerance (IGT)
  • Metformin
  • Prediabetes
  • Review

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Metformin for diabetes prevention : insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. / for the Diabetes Prevention Program Research Group.

In: Diabetologia, Vol. 60, No. 9, 01.09.2017, p. 1601-1611.

Research output: Contribution to journalReview article

for the Diabetes Prevention Program Research Group. / Metformin for diabetes prevention : insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. In: Diabetologia. 2017 ; Vol. 60, No. 9. pp. 1601-1611.
@article{91992e43983b4636848a90455d748bec,
title = "Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study",
abstract = "The largest and longest clinical trial of metformin for the prevention of diabetes is the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study (DPP/DPPOS). In this review, we summarise data from the DPP/DPPOS, focusing on metformin for diabetes prevention, as well as its long-term glycaemic and cardiometabolic effects and safety in people at high-risk of developing diabetes. The DPP (1996–2001) was a RCT of 3234 adults who, at baseline, were at high-risk of developing diabetes. Participants were assigned to masked placebo (n = 1082) or metformin (n = 1073) 850 mg twice daily, or intensive lifestyle intervention (n = 1079). The masked metformin/placebo intervention phase ended approximately 1 year ahead of schedule because of demonstrated efficacy. Primary outcome was reported at 2.8 years. At the end of the DPP, all participants were offered lifestyle education and 88{\%} (n = 2776) of the surviving DPP cohort continued follow-up in the DPPOS. Participants originally assigned to metformin continued to receive metformin, unmasked. The DPP/DPPOS cohort has now been followed for over 15 years with prospective assessment of glycaemic, cardiometabolic, health economic and safety outcomes. After an average follow-up of 2.8 years, metformin reduced the incidence of diabetes by 31{\%} compared with placebo, with a greater effect in those who were more obese, had a higher fasting glucose or a history of gestational diabetes. The DPPOS addressed the longer-term effects of metformin, showing a risk reduction of 18{\%} over 10 and 15 years post-randomisation. Metformin treatment for diabetes prevention was estimated to be cost-saving. At 15 years, lack of progression to diabetes was associated with a 28{\%} lower risk of microvascular complications across treatment arms, a reduction that was no different among treatment groups. Recent findings suggest metformin may reduce atherosclerosis development in men. Originally used for the treatment of type 2 diabetes, metformin, now proven to prevent or delay diabetes, may serve as an important tool in battling the growing diabetes epidemic. Long-term follow-up, currently underway in the DPP/DPPOS, is now evaluating metformin’s potential role, when started early in the spectrum of dysglycaemia, on later-stage comorbidities, including cardiovascular disease and cancer. Trial registration: ClinicalTrials.gov NCT00038727 and NCT00004992.",
keywords = "Diabetes prevention, DPP, DPPOS, Impaired glucose tolerance (IGT), Metformin, Prediabetes, Review",
author = "{for the Diabetes Prevention Program Research Group} and Aroda, {Vanita R.} and Knowler, {William C.} and Crandall, {Jill P.} and Leigh Perreault and Edelstein, {Sharon L.} and Jeffries, {Susan L.} and Molitch, {Mark E.} and Xavier Pi-Sunyer and Christine Darwin and Heckman-Stoddard, {Brandy M.} and Marinella Temprosa and Kahn, {Steven E.} and Nathan, {David M.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s00125-017-4361-9",
language = "English (US)",
volume = "60",
pages = "1601--1611",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Metformin for diabetes prevention

T2 - insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study

AU - for the Diabetes Prevention Program Research Group

AU - Aroda, Vanita R.

AU - Knowler, William C.

AU - Crandall, Jill P.

AU - Perreault, Leigh

AU - Edelstein, Sharon L.

AU - Jeffries, Susan L.

AU - Molitch, Mark E.

AU - Pi-Sunyer, Xavier

AU - Darwin, Christine

AU - Heckman-Stoddard, Brandy M.

AU - Temprosa, Marinella

AU - Kahn, Steven E.

AU - Nathan, David M.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - The largest and longest clinical trial of metformin for the prevention of diabetes is the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study (DPP/DPPOS). In this review, we summarise data from the DPP/DPPOS, focusing on metformin for diabetes prevention, as well as its long-term glycaemic and cardiometabolic effects and safety in people at high-risk of developing diabetes. The DPP (1996–2001) was a RCT of 3234 adults who, at baseline, were at high-risk of developing diabetes. Participants were assigned to masked placebo (n = 1082) or metformin (n = 1073) 850 mg twice daily, or intensive lifestyle intervention (n = 1079). The masked metformin/placebo intervention phase ended approximately 1 year ahead of schedule because of demonstrated efficacy. Primary outcome was reported at 2.8 years. At the end of the DPP, all participants were offered lifestyle education and 88% (n = 2776) of the surviving DPP cohort continued follow-up in the DPPOS. Participants originally assigned to metformin continued to receive metformin, unmasked. The DPP/DPPOS cohort has now been followed for over 15 years with prospective assessment of glycaemic, cardiometabolic, health economic and safety outcomes. After an average follow-up of 2.8 years, metformin reduced the incidence of diabetes by 31% compared with placebo, with a greater effect in those who were more obese, had a higher fasting glucose or a history of gestational diabetes. The DPPOS addressed the longer-term effects of metformin, showing a risk reduction of 18% over 10 and 15 years post-randomisation. Metformin treatment for diabetes prevention was estimated to be cost-saving. At 15 years, lack of progression to diabetes was associated with a 28% lower risk of microvascular complications across treatment arms, a reduction that was no different among treatment groups. Recent findings suggest metformin may reduce atherosclerosis development in men. Originally used for the treatment of type 2 diabetes, metformin, now proven to prevent or delay diabetes, may serve as an important tool in battling the growing diabetes epidemic. Long-term follow-up, currently underway in the DPP/DPPOS, is now evaluating metformin’s potential role, when started early in the spectrum of dysglycaemia, on later-stage comorbidities, including cardiovascular disease and cancer. Trial registration: ClinicalTrials.gov NCT00038727 and NCT00004992.

AB - The largest and longest clinical trial of metformin for the prevention of diabetes is the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study (DPP/DPPOS). In this review, we summarise data from the DPP/DPPOS, focusing on metformin for diabetes prevention, as well as its long-term glycaemic and cardiometabolic effects and safety in people at high-risk of developing diabetes. The DPP (1996–2001) was a RCT of 3234 adults who, at baseline, were at high-risk of developing diabetes. Participants were assigned to masked placebo (n = 1082) or metformin (n = 1073) 850 mg twice daily, or intensive lifestyle intervention (n = 1079). The masked metformin/placebo intervention phase ended approximately 1 year ahead of schedule because of demonstrated efficacy. Primary outcome was reported at 2.8 years. At the end of the DPP, all participants were offered lifestyle education and 88% (n = 2776) of the surviving DPP cohort continued follow-up in the DPPOS. Participants originally assigned to metformin continued to receive metformin, unmasked. The DPP/DPPOS cohort has now been followed for over 15 years with prospective assessment of glycaemic, cardiometabolic, health economic and safety outcomes. After an average follow-up of 2.8 years, metformin reduced the incidence of diabetes by 31% compared with placebo, with a greater effect in those who were more obese, had a higher fasting glucose or a history of gestational diabetes. The DPPOS addressed the longer-term effects of metformin, showing a risk reduction of 18% over 10 and 15 years post-randomisation. Metformin treatment for diabetes prevention was estimated to be cost-saving. At 15 years, lack of progression to diabetes was associated with a 28% lower risk of microvascular complications across treatment arms, a reduction that was no different among treatment groups. Recent findings suggest metformin may reduce atherosclerosis development in men. Originally used for the treatment of type 2 diabetes, metformin, now proven to prevent or delay diabetes, may serve as an important tool in battling the growing diabetes epidemic. Long-term follow-up, currently underway in the DPP/DPPOS, is now evaluating metformin’s potential role, when started early in the spectrum of dysglycaemia, on later-stage comorbidities, including cardiovascular disease and cancer. Trial registration: ClinicalTrials.gov NCT00038727 and NCT00004992.

KW - Diabetes prevention

KW - DPP

KW - DPPOS

KW - Impaired glucose tolerance (IGT)

KW - Metformin

KW - Prediabetes

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85026778634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026778634&partnerID=8YFLogxK

U2 - 10.1007/s00125-017-4361-9

DO - 10.1007/s00125-017-4361-9

M3 - Review article

C2 - 28770322

AN - SCOPUS:85026778634

VL - 60

SP - 1601

EP - 1611

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 9

ER -